{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-034556","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.180461+00:00","generated_at":"2026-06-13T02:19:08.876580+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alkermes Q2 2023 revenues $617.4M, GAAP net income $237.1M on arbitration win","bullets":["Total revenues $617.4M including $248.4M back royalties from Janssen arbitration; proprietary product sales up 21% YoY to $231.5M.","GAAP net income $237.1M ($1.43 basic EPS) vs net loss $30.1M in Q2 2022; non-GAAP net income $94.3M ($0.57 EPS).","LYBALVI net sales $47.0M (+134% YoY); VIVITROL $102.1M (+6%); ARISTADA $82.4M (+10%).","Cash and investments $907.2M; FY 2023 financial expectations reiterated, including accretive INVEGA royalties.","Oncology separation into Mural Oncology on track for H2 2023; Caroline Loew appointed CEO designate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-034556","json":"https://secwatch.observer/filing/0000950170-23-034556.json","markdown":"https://secwatch.observer/filing/0000950170-23-034556.md","text":"https://secwatch.observer/filing/0000950170-23-034556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023034556/0000950170-23-034556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023034556/alks-20230726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:19:08.876580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"468af2a6eda020e2d7f805c978cf9edbea2622e7","claim":"Alkermes plc. updated its three and six months ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On July 26, 2023, Alkermes plc (the “Company”) announced financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023034556/0000950170-23-034556-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}